Systemic reactions to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis and/or asthma: A real‐life, multi‐center study

Ähnliche Einträge

• Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis
  von: Nan Wang, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis
  von: Koki Sasamoto, et al.
  Veröffentlicht: (2024)
• One‐strength dose escalation of house dust mite depot product for subcutaneous immunotherapy is safe and tolerable
  von: M. Jutel, et al.
  Veröffentlicht: (2024)
• Editorial comment on “Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1–4 years old children with perennial allergic rhinitis”
  von: Umit Murat Sahiner, et al.
  Veröffentlicht: (2024)
• Treatment of allergic rhinitis with allergen immunotherapy in children and adolescents—Adherence, rhinitis severity, and asthma onset
  von: Anna M. Hedman, et al.
  Veröffentlicht: (2026)